SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 7.0500.0%Dec 6 12:00 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (2918)10/18/2011 12:09:56 PM
From: richardred1 Recommendation  Read Replies (1) of 6521
 
GlaxoSmithKline to Make a Bid for Human Genome Sciences?
wscs

* Human Genome Sciences : The shares recently traded at $12.97, up $1.72, or 15.56%, on the day. The shares have traded in a 52-week range of $10.40 to $30.15 and its market capitalization is $2.47 billion. About the company: Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes.
* GlaxoSmithKline : The shares recently traded at $42.98, down $0.25, or 0.58%, on the day. The shares have traded in a 52-week range of $36.28 to $45.34 and its market capitalization is $109.82 billion. About the company: GlaxoSmithKline plc is a research-based pharmaceutical group that develops, manufactures and markets vaccines, prescription and over-the-counter medicines, as well as health-related consumer products. The Group, which also provides laboratory testing and disease management services, specializes in treatments for respiratory, central nervous system, gastro-intestinal and genetic disorders.
finance.yahoo.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext